Paul S. Herendeen

2016 - Valeant Pharmaceuticals International

In 2016, Paul S. Herendeen earned a total compensation of $31.4M as Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals International.

Compensation breakdown

Bonus$10,400,000
Option Awards$15,937,869
Salary$346,154
Stock Awards$4,690,500
Total$31,374,523

Herendeen received $15.9M in option awards, accounting for 50.80% of the total pay in 2016.

Herendeen also received $10.4M in bonus, $346.2K in salary and $4.7M in stock awards.

Rankings

In 2016, Paul S. Herendeen's compensation ranked 40th out of 14,063 executive pay records tracked by us. In other words, Herendeen earned more than 99.7% of all executives tracked by us in 2016.

ClassificationRankingPercentile
All
40
out of 14,063
100th
Manufacturing
Division
9
out of 5,498
100th
Chemicals And Allied Products
Major group
4
out of 1,871
100th
Drugs
Industry group
3
out of 1,505
100th
Pharmaceutical Preparations
Industry
3
out of 1,147
100th
Source: SEC filing on March 21, 2018.

Herendeen's colleagues

We found two more compensation records of executives who worked with Paul S. Herendeen at Valeant Pharmaceuticals International in 2016.

2016

Joseph Papa

Valeant Pharmaceuticals International

Chief Executive Officer

2016

Christina Ackermann

Valeant Pharmaceuticals International

General Counsel

News

In-depth

You may also like